The tweet was deleted by the author.
But we saved everything 🙂.
Greenwich LifeSciences announces an increase in the patient screening rate for its ongoing FLAMINGO-01 clinical trial.
The company is advancing the enrollment phase, as reflected in the expanded screening activity. The FLAMINGO-01 study is a key part of Greenwich LifeSciences' development efforts in oncology. The latest update highlights strengthened operational momentum as the trial progresses toward its next milestones. Further details on the impact of the increased screen rate have not yet been disclosed.